Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSCEND PEDALL of JCAR017 in pediatric relapsed/refractory B-ALL and B-cell NHL
NL-OMON48667Phase 2Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Dec 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lisocabtagene maraleucel in B cell acute lymphoblastic leukemia (B-ALL), mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL) and 2 more, sponsored by Celgene Corporation. Primary endpoints: Recommended Phase 2 dose, Pharmacokinetics and 4 more. Started Dec 2021; status: active, not recruiting.
02
Drugs
lisocabtagene maraleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)Burkitt lymphoma (BL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NL-OMON48667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48667.